Clinical Trials Logo

Anaplastic Ependymoma clinical trials

View clinical trials related to Anaplastic Ependymoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01295944 Completed - Ependymoma Clinical Trials

Carboplatin and Bevacizumab for Recurrent Ependymoma

Start date: April 27, 2011
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if the combination of bevacizumab and carboplatin can help to control recurrent ependymoma. The safety of this drug combination will also be studied.

NCT ID: NCT01082926 Completed - Glioblastoma Clinical Trials

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

Start date: May 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. Donor T cells that are treated in the laboratory may be effective treatment for malignant glioma. Aldesleukin may stimulate the white blood cells to kill tumor cells. Combining different types of biological therapies may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best way to give therapeutic donor lymphocytes together with aldesleukin in treating patients with stage III or stage IV malignant glioma.